I started Urolithin A, and really can’t notice any effects.
1 Like
Which brand is this, the name, manufacturer, dosage?
I am ultra sensitive to all supplements and meds so perhaps it is just me.
You might want to try the UA made by Neurogena.
Mitopure. I don’t know why it costs twice as much as the one from Neurogena… doesnt seem to be very effective.
I tried the Neurogena brand. Maybe it’s just not for me.
CJZ
#268
Generally a well regarded company in my other groups, been on Q&As with the owner. Here’s the product: Undefined Relief with MitoCure Rx Treatments – Wizard Sciences. it’s supposed to have the full dose of Urolithin plus some other supplements which make reasonable sense to combine.
Neo
#269
@CJZ @francesss7ca UA is a bit more like a medicine than a supplement in the sense that they managed to get a lot of patents for it. So perhaps try and see if they have a license to the patents - otherwise it would be rare for a super legit entity to also be a patent infringer.
I’ve read it may take up to 8 weeks to notice
1 Like
Thiago
#271
The same here.
I tested for one year. For periods, even 1g a day and nothing.
The gains in the studies are quite small and in some they even had better gains in the 500mg dose against 1g.
The idea is brilliant though. Also now they are trying to provide the test if you have a gut absorption, but I am afraid of the accuracy of this test.
1 Like
AnUser
#272
1 Like
The patents is for a use. That only really affects marketing. People can sell UA as long as they dont say what it is for.
JuanDaw
#274
Lost my interest after listening to Mark Tarnopolsy, MD, from the vid uploaded by John Hemming.
1 Like
adssx
#275
Mitochondrial and Microtubule Defects in Exfoliation Glaucoma 2024
Preprint
Treatment of XFG TFs with a mitophagy inducer, Urolithin A, and a mitochondrial biogenesis inducer, NAD+ precursor, Nicotinamide Ribose, improved mitochondrial bioenergetics and reduced ROS accumulation. Our results demonstrate abnormal mitochondria in XFG TFs and suggest that mitophagy inducers may represent a potential class of therapeutics for reversing mitochondrial dysfunction in XFG patients.
Modulating Human Skeletal Muscle with Loading and Unloading 2024
PhD thesis
In the first clinical trial to administer the natural post-biotic Urolithin A during immobilization, a nutritional beverage with Urolithin A did not mitigate immobilization-induced reductions in mitochondrial content, muscle size, muscle protein synthesis, and muscle function.
2 Likes
From the most recent ARDD, a new video just uploaded to the ARDD YouTube channel:
1 Like
LukeMV
#277
You only took 1mg of Rapamycin? Are you sure the fatigue was from that? That’s just a small dose.
Bicep
#278
And it was Siroboon at that .
Yes 1 mg. I am sensitive to supps. I plan on starting again and see if i can get used to it…i want to see if it will help my eyes.
Has anyone gone the rabbit hole of figuring out the optimal way to boost these specific strains?
1 Like
Urolithin A Derivatives Targeting Mitophagy in Clinical Trials
While there seems to be no firmly established mechanism by which urolithin A acts to modestly improve mitochondrial function, it seems presumed that this (and a number of other compounds, such as mitoQ) largely function via improving the operation of mitophagy. Mitophagy, mitochondrially targeted autophagy, is a maintenance process that removes damaged and worn mitochondria. Too little of that and the mitochondrial population in a cell become incrementally more dysfunctional. Impaired mitophagy and mitochondrial dysfunction are features of aging, while improved autophagy is a feature of cell stress responses and many interventions known to modestly slow aging in animal studies.
Vandria is one of a number of companies attempting to make therapies for age-related conditions based on novel modifications of established autophagy or mitophagy promoting compounds. Here, Vandria is noted to have started an initial clinical trial for a urolithin A derivative. So far, efforts in this direction have failed to improve on calorie restriction, and only the rapalogs have done better in some aspects than exercise. It remains to be seen as to how this line of work will fare. Certainly, the original urolithin A compound isn’t all that impressive in animal studies.
=================
Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
VNA-318 is an orally available first-in-class small molecule against a novel target to rejuvenate cells and treat age-related diseases through the induction of mitophagy. The target has strong genetic links to several human diseases including Alzheimer’s disease. It has a dual mode of action with an immediate improvement of memory, learning, and cognitive function, paired with long-term disease-modifying effects such as reduced neuroinflammation, less toxic protein aggregation, and improved mitochondrial function, as shown in pre-clinical models of Alzheimer’s and Parkinson’s disease. Toxicity studies have demonstrated VNA-318 has a wide safety window. A composition of matter patent covering VNA-318 and other compounds has been issued by the US Patent Office.
This Phase 1 randomized, double-blind trial is a combined single and multiple ascending dose trial of VNA-318, designed to assess safety, tolerability, pharmacokinetic, and pharmacodynamic parameters in healthy male subjects.
Company Website:
3 Likes
